Human Irisin ELISA Kit | EL-213-09

Cat. No: EL-213-09

$859.99 USD

96 wells

1
Target proteinIrisin
Alternative nameFNDC5
Gene ID252995
ReactivityHuman
Detection range0.32-20 ng/mL
Sample typeserum, plasma, tissue homogenates and other biological fluids
Sample volume100 µL
Assay time3h 20min
PrecisionIntra-assay CV <8%. Inter-assay CV <10%
ComponentsPre-Coated Microplate - 12 strips x 8 wells (4°C/-20°C)
Standard (Lyophilized) - 2 vials (4°C/-20°C)
Biotinylated Antibody (100×) - 120 μL (4°C/-20°C)
Streptavidin-HRP (100×) - 120 μL (4°C/-20°C)
Standard/Sample Diluent Buffer - 20 mL (4°C/-20°C)
Biotinylated Antibody Diluent - 12 mL (4°C/-20°C)
HRP Diluent - 12 mL (4°C/-20°C)
Wash Buffer (25×) - 20 mL (4°C/-20°C)
TMB Substrate Solution - 10 mL (4°C/-20°C (store in dark))
Stop Reagent - 6 mL (4°C/-20°C)
Plate Covers - 2 pieces (RT)
Storage4°C/-20°C

Download product sheet (PDF)

Safety Warning: Research Use Only. Not for diagnostic use.

This kit employs a sandwich enzyme immunoassay technique to quantify Human Irisin in biological samples.

Introduction

Irisin is the circulating hormone fragment released from FNDC5, a muscle-membrane protein initially made as a roughly 212-residue precursor with an extracellular fibronectin type III domain, a single transmembrane segment, and a short cytoplasmic tail. Physical exertion drives proteolytic shedding of the extracellular portion into the bloodstream as a glycosylated, approximately 12 kDa peptide, giving irisin its identity as an exercise-induced myokine. Once released, it acts on adipose tissue to promote a shift from white to brown-like fat by raising UCP1 levels, partly through PPARA signaling, and irisin-linked MAPK activity has separately been tied to bone formation and neuronal differentiation. FNDC5 transcripts undergo alternative splicing, and translation of the human precursor unusually begins from a non-AUG start codon that functions as an ordinary AUG start site in other species.

Principle of the Assay

This kit utilizes a sandwich enzyme immunoassay format in which the microtiter plate wells are pre-coated with a capture antibody specific to Human Irisin. Standards or samples are pipetted into the appropriate wells alongside a biotin-conjugated detection antibody that also recognizes Human Irisin. Avidin conjugated to horseradish peroxidase (HRP) is then added to each well and allowed to incubate, linking enzymatic activity to any captured analyte via the biotin–avidin interaction. Upon addition of TMB substrate solution, a colorimetric signal develops exclusively in wells where Human Irisin, the biotin-conjugated antibody, and the HRP-conjugated avidin are all present. The enzymatic reaction is stopped by the addition of a sulphuric acid solution, and absorbance is read spectrophotometrically at 450 nm (± 10 nm). Human Irisin concentrations in the samples are determined by interpolating the measured optical densities against a standard curve.